Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

GB00BYMT0J19
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG009LGHG16
LIVN
LivaNova PLC
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medical Devices · THEMEFOLIO: $HLTH
NAME
LivaNova PLC
ISIN
GB00BYMT0J19
TICKER
LIVN
MIC
XNAS
REUTERS
LIVN.OQ
BLOOMBERG
LIVN US
Wed, 24.06.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova....
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when treated with proximal hypoglossal nerve stimulat...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company’s Board of Directors after its Annual General Meeting of shareholders on June 10. “We’re pleased to welcome Jette to LivaNova’s Board,” said William Kozy, Chair. “She brings deep medtech governance expertise,...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.06.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy brings more than two decades of experience advisin...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership trans...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.05.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Developmen...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to th...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company’s OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulatio...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 25.02.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $360.9 million increased 12.1% on a reported basis and 9.5% on both a constant-currency and organic basis as compar...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.01.2026       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call. The audiocast will b...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.12.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. “Lucile is an accomplish...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.11.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Stan...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assigned VNS Therapy™, a LivaNova neuromodulation treatment for patients 4 years of age and older with Drug-Resistant Epilepsy (DRE) and focal seizures, to New Technology Ambulatory Payment Clas...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan. “We are confident in our ability to deliver on the targets we outlined today. LivaNova’s talented team is focused on a revitalized innovation strategy and op...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an o...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Wolfe Research Healthcare Conference 2025 in New York City. The presentation will take place...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 08.10.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5, 2025, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.co...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.10.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis. The Company will present a five-year analysis of the THN-3 randomized control trial (RCT), which studied the use of its aura6000™ System for the treatmen...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.09.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company’s Board of Directors, effective today. Zurbay will serve on the Audit and Compliance Committee for the Board. “LivaNova is pleased to welcome Don to our Board of Directors,” said William Kozy, Chair of the Boa...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.08.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025, beginning at 9 a.m. EST until approximately 1 p.m. EST in New York City and via webcast. Members of the executive leadership team, including Chief Executive Officer Vladimir Makatsaria...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.08.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during fireside chats at the two following September healthcare conferences in New York City: Baird 2025 Global Healthc...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.08.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it initiated the commercial launch of the Essenz™ Perfusion System in China, the second-largest market for LivaNova heart-lung machines (HLMs) after the United States. The Essenz Perfusion System, which recently received regulatory approval from China’s Natio...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.07.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova....
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.06.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than 800 people with epilepsy treated with VNS Therapy™ worldwide. With the clinical study report (CSR) now complete, the final 36-month data further validate...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.06.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) from the CORE-VNS three-year study have been published in Epilepsia1. Several CORE-VNS study findings were highlighted in the recent article on GTC se...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.06.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar patients with treatment-resistant depression (TRD). The first step in the process fo...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all i...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organi...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% w...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.03.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/event...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.02.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.01.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be a...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.01.2025       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. “Natalia...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.12.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on quality...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.12.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10 in Los Angeles. The Company’s therapies and technologies for drug-resistant epilepsy treatment will be featured in numerous scientific posters to support...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.11.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in November and December: Stifel Healthcare Conference 2024 on Tuesday, November 19 from 11...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.11.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary end...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.10.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year pe...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.10.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. “LivaNova’s Board of Directors is pleased to welcome Susan Podlogar,” said William Kozy...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.09.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova....
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.08.2024       LivaNova
GB00BYMT0J19

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Baird 2024 Global Healthcare Conference in New York. The presentation will take place at 10:15 a.m. Eastern Time on Tuesday, September 10. The discussion will be available...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Sun, 28.07.2024       LivaNova
GB00BYMT0J19

New York, New York--(Newsfile Corp. - July 28, 2024) - Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LivaNova and certain of its...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.07.2024       LivaNova
GB00BYMT0J19

New York, New York--(Newsfile Corp. - July 16, 2024) - Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether LivaNova and certain of its of...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.07.2024       LivaNova
GB00BYMT0J19

New York, New York--(Newsfile Corp. - July 8, 2024) - Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LivaNova and certain of its...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.06.2024       LivaNova
GB00BYMT0J19

New York, New York--(Newsfile Corp. - June 28, 2024) - Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LivaNova and certain of its...
Read more
LivaNova
Technical Analysis Termsheets Terminal
Permalink